Labarai

Caesarea, Isra'ila, Yuni 13, 2022 / PRNewswire/ - IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" ko "Kamfanin"), ƙananan ƙwayoyin cuta ("IceCure (Shanghai) MedTech Co. . , Ltd. ("IceCure", wani kamfani na IceCure (Shanghai) MedTech Co., Ltd. Shanghai"), ya sanya hannu kan kwangilar gina IceSense3 cryoablation tsarin tare da Shanghai Medtronic Zhikang Medical Devices Co., Ltd. ("Shanghai"). Medtronic), wani reshen Kamfanin Medtronic (NYSE: MDT) ("Medtronic") da Beijing Turing Medical Technology Co., Ltd. ("Turing") ana sa ran isar da tsarin IceSense3 na farko a cikin 2022.
Medtronic Shanghai za ta zama kadai mai rarraba IceSense3 da binciken da za a iya zubarwa a cikin babban yankin kasar Sin na tsawon shekaru uku na farko, tare da mafi karancin sayan dala miliyan 3.5 a wannan lokacin. Bugu da kari, a babban yankin kasar Sin, Shanghai Medtronic ba za ta saka hannun jari kai tsaye ko a kaikaice ba ko ciniki, sayarwa, kasuwa, tallata ko bayar da duk wani samfurin da ya yi gogayya da IceSense3 a lokacin yarjejeniyar rarraba da kuma bayan watanni shida (6). Turing zai dauki nauyin shigo da kaya, shigarwa da bayan-tallace-tallace na tsarin IceSense3 a babban yankin kasar Sin, yayin da Medtronic Shanghai za ta kula da duk tallace-tallace, tallace-tallace da wasu horo na sana'a.
Hukumar Kula da Kayayyakin Kiwon Lafiya ta kasar Sin ("NMPA") ta amince da IceSense3 System Console. IceCure ta nemi canjin takardar shedar rajista don amincewa da binciken da za a iya zubarwa wanda, idan an amince da shi, zai ba wa kamfanin damar tallata IceSense3 cryoprobes na zubar da ciki don amfanin kasuwanci, kuma IceCure yana tsammanin samun amincewar NMPA don binciken a ƙarshen 2022.
"Shanghai Medtronic da Turing abokan hulɗa ne masu kyau a gare mu a babban yankin kasar Sin, inda kasuwar fasahar cryoablation ba ta da yawa a halin yanzu. Muna ganin kyakkyawar dama ga yaduwar tsarin mu na IceSense3 cryoablation a babban yankin kasar Sin, kasuwar da ke girma cikin sauri. wanda ke inganta sakamako, "in ji Shugaban Kamfanin IceCure Eyal Shamir. "A matsayin wani ɓangare na babban kamfanin na'urorin kiwon lafiya na duniya, Shanghai Medtronic yana da ƙwarewa da ikon kasuwa don ba da damar shigar da sauri cikin kasuwa na IceSense3 don samar da lafiya, inganci da tsadar magani don ciwon nono na farko da sauran alamomi."
Jing Yu, mataimakin shugaban kasa kuma babban manajan Skull, Spine and Orthopedic Technologies a Medtronic Shanghai ya ce "IceCure yana da babbar hanyar magance ciwon kumburi a duniya." Haɗin gwiwa tare da IceCure da Turing Medical za su dace da layin samfuran Medtronic Shanghai a cikin cututtukan cututtukan cututtukan cututtukan ƙwayar cuta. Muna fatan cewa wannan haɗin gwiwar zai ci gaba da aikace-aikacen asibiti na cryoablation da kuma amfana da ƙarin masu ciwon daji, kuma muna sa ran yin aiki tare da ƙarin abokan tarayya don haɓaka haɓakawa da ƙaddamar da hanyoyin magance matsalolin kiwon lafiya da za su taimaka wajen magance matsalolin maganin ciwon daji. Sashin lafiya na kasar Sin.
Babban jami'in Turing Lin Youjia ya kara da cewa, "tare da hadin gwiwar Shanghai Medtronic da IceCure, mun himmatu wajen fara jigilar kayayyaki da saurin shigar da tsarin IceSense3 a babban yankin kasar Sin. Kasancewarmu a duk fadin kasar Sin yana tabbatar da cewa cibiyoyin kiwon lafiya sun sami tallafin fasaha kuma suna amfani da tsarin IceSense3 na dogon lokaci."
A ranar 12 ga Yuni, 2022 ("Kwanan da suka dace"), IceCure Shanghai sun shiga yarjejeniyar tallace-tallace da rarrabawa ta musamman ("Yarjejeniyar Rarraba") tare da Shanghai Medtronic da Turing don IceSense3 da bincike na zubarwa ("Kayayyakin") na farkon lokaci. Watanni 36, mafi ƙarancin maƙasudin siyayya na wannan lokacin shine $3.5 miliyan ("Mafi ƙanƙantar sayayya"). A karkashin yarjejeniyar rarraba IceCure Shanghai za ta sayar da kayayyakin Turing sannan Turing za ta shigo da kayayyaki daga Isra'ila zuwa babban yankin kasar Sin sannan ta sake sayar da su zuwa Medtronic Shanghai. Medtronic Shanghai za ta dauki nauyin, a tsakanin sauran abubuwa: (i) tallatawa da tallata samfurin a babban yankin kasar Sin; (ii) gudanar da ayyukan ƙwararrun ilimin likitanci don samfurin a cikin babban yankin Sin. Turing zai dauki nauyin ajiyar kaya, dabaru, garanti, horo da sauran tallafi da sabis na tallace-tallace.
A karkashin yarjejeniyar rabon, Shanghai Medtronic na da hakkin tsawaita wa'adin yarjejeniyar rabon har na tsawon shekaru uku, idan har ta kai ga adadin mafi karancin shekaru uku na sayayya, bisa yarjejeniyar da aka cimma sabon mafi karancin saye. Ana iya dakatar da Yarjejeniyar Mai Rarraba a ƙarƙashin wasu yanayi, gami da abin da ya faru na tsoho, tsoho kayan aiki ko rashin biyan kuɗi.
Bugu da kari, bisa ga sharuddan yarjejeniyar Rarraba, IceCure Shanghai za ta dauki nauyin samun da kuma kiyaye duk wani izini na ka'idoji ("Yin Amincewa da Ka'ida") da ake buƙata don kasuwa, haɓakawa, rarrabawa, siyarwa da amfani da samfuran a babban yankin Sin. NMPA, reshenta na gida, ko kowace hukumar gwamnati ("Hukumar Kulawa"). IceCure Shanghai ta sami amincewar tsari don IceSense3 System Console kuma yana buƙatar amincewar tsari don IceSense3 cryoprobe da za a iya zubarwa don hanyoyin kasuwanci cikin watanni tara daga ranar da aka cimma yarjejeniyar rarraba. Shanghai Medtronic yana da hakkin ya dakatar da yarjejeniyar rarrabawa idan IceCure Shanghai bai sami amincewar tsari na cryoprobes a lokacin ba.
Likitan IceCure (NASDAQ: ICCM) (TASE: ICCM) yana haɓakawa kuma yana tallata ProSense®, ci-gaban ruwa nitrogen cryoablative far don kula da ciwace-ciwacen daji (m da ciwon daji) tare da cryotherapy, da farko niyya nono, koda, kashi da cututtukan huhu. crayfish. Ƙwararriyar fasahar sa ta ba da amintacciyar hanya mai inganci ga tiyatar kawar da ƙari na marasa lafiya, tare da ɗan gajeren lokacin aiki da kuma hanyar fiɗa mai sauƙi don aiwatarwa. Har zuwa yau, ana siyar da tsarin kuma ana tallata shi a duk duniya don alamun da aka yarda da FDA kuma an amince da Mark Mark a Turai.
Wannan sanarwar manema labarai ta ƙunshi kalamai masu sa ido a cikin ma'anar "tashar jiragen ruwa mai aminci" na Dokar Sake Gyara Shari'a na Securities na 1995 da sauran dokokin tsaro na tarayya. Kalmomi kamar su “tsammani”, “tsalle”, “nufi”, “tsari”, “yi imani”, “ƙididdigewa”, “ƙimantawa” da makamantansu maganganu ko bambancin irin waɗannan kalmomi ana nufin yin nuni ga maganganun sa ido. Misali, IceCure yana amfani da maganganun sa ido a cikin wannan sanarwar manema labarai lokacin da ake tattaunawa kan yarjejeniyoyin rarrabawa tare da Shanghai Medtronic da Turing, dabarun gudanarwa na kamfanin, ayyukan tallace-tallace, da damar kasuwa don tsarin kukan da kamfanin ke yi a babban yankin kasar Sin. Saboda irin waɗannan maganganun suna da alaƙa da abubuwan da suka faru a nan gaba kuma sun dogara ne akan tsammanin IceCure na yanzu, suna fuskantar haɗari daban-daban da rashin tabbas, kuma ainihin sakamakon IceCure, aiki ko nasarorin na iya bambanta da waɗanda aka bayyana ko kuma suka bayyana ta bayanan da ke cikin wannan sanarwar manema labarai. Akwai bambance-bambance masu mahimmanci. . Maganganun neman gaba da ke ƙunshe ko fayyace a cikin wannan sanarwar manema labarai suna ƙarƙashin wasu haɗari da rashin tabbas, waɗanda da yawa daga cikinsu sun fi ƙarfin ikon Kamfanin, gami da waɗanda aka bayyana a cikin sashin “Abubuwan Hatsari” na Rahoton Shekara-shekara na Kamfanin akan Form 20-F da aka shigar a ciki. SEC har zuwa Afrilu 1, 2022 na shekarar da ta ƙare Disamba 31, 2021, akwai akan gidan yanar gizon SEC a www.sec.gov. Kamfanin ba ya ɗaukar kowane nauyi don sabunta waɗannan maganganun don bita ko canje-canje bayan kwanan wata sanarwar manema labarai, sai dai idan doka ta buƙaci yin haka.